Drug Approval | May 14, 2025
Briefs: Zydus and CuraTeQ Biologics
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
The FDA issued Form 483 with one observation related to building and facility management
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The Subsidiary has received one inspectional observation in Form 483
Investment demonstrates confidence in America’s commitment to science and innovation
Subscribe To Our Newsletter & Stay Updated
